| Page 15 | Aplastic Anemia & MDS International Foundation Return to top.

2022 Buffalo Patient and Family Hybrid Conference

Find links to the recordings from the sessions at the 2022 Patient and Family Hybrid Conference below.

Living with Aplastic Anemia

Living with Low-Risk MDS

Event Date: 
Sat, 09/10/2022 - 3:00pm (EDT)

Press Release Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.

Share with addtoany.com.